Ignite Creation Date:
2024-05-06 @ 6:00 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05511844
Status:
RECRUITING
Last Update Posted:
2024-04-01
First Post:
2022-08-17
Brief Title:
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Sponsor:
Orum Therapeutics USA Inc
Organization:
Orum Therapeutics USA Inc
Study Overview
Official Title:
Phase I Multicenter Open-Label First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors The study consists of two parts a Part 1 Dose Escalation and Part 2 Dose Expansion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None